• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Sao Paulo Medical Journal >Gefitinib (Iressa?) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center
【24h】

Gefitinib (Iressa?) in metastatic patients with non-small cell lung cancer: preliminary experience in a Brazilian center

机译：吉非替尼（Iressa？）在非小细胞肺癌转移患者中的研究：在巴西中心的初步经验

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

CONTEXT: Patients with metastatic non-small cell lung cancer are deemed incurable, but they may derive some benefit from systemic palliative chemotherapy. Recently, with the introduction of epidermal growth factor receptor (EGFR) antagonists such as gefitinib (Iressa?), an effective and less toxic option is now available for the treatment of such patients. OBJECTIVE: To assess the activity and toxicity of gefitinib in a group of Brazilian patients. TYPE OF STUDY: Prospective, open label, non-randomized and non-controlled. SETTING: Clínica de Oncologia e Hematologia (CLIOH), S?o Paulo, Brazil. PATIENTS AND METHODS: From June 2002 to April 2003 we treated five patients with metastatic previously-treated non-small cell lung cancer (median of two previous chemotherapy regimens), using gefitinib at a dose of 250 mg orally on a daily basis, within a compassionate protocol sponsored by AstraZeneca. The patients' median age was 65 years and two of them were male. Three had a performance status of 1, one of 2 and one of 3, on the ECOG (Eastern Cooperative Oncology Group) scale. RESULTS: We observed skin rash in two patients, diarrhea in three and arthralgia in two. One patient had a partial response and another had stabilization of her disease, as measured via imaging studies (which have lasted for more than 11 and 4 months, respectively), which were accompanied by significant decrease in tumor markers, whereas three patients worsened during treatment. DISCUSSION: New options of chemotherapy agents with favorable toxicity profiles are urgently needed for the treatment of metastatic non-small lung cancer patients who usually have short life expectancies. In our small series of five patients, we observed stabilization of the disease in two of them and the skin and gastrointestinal reactions often described in the literature in all of them. Two had arthralgia, not reported before. CONCLUSION: We concluded that gefitinib is an important addition to the therapeutic armamentarium for patients with metastatic non-small cell lung cancer.
机译：背景：转移性非小细胞肺癌患者被认为是无法治愈的，但他们可能从全身姑息化疗中获益。最近，随着表皮生长因子受体（EGFR）拮抗剂的引入，例如吉非替尼（Iressa？），一种有效且毒性较小的选择现在可用于治疗此类患者。目的：评估吉非替尼在一组巴西患者中的活性和毒性。研究类型：前瞻性，开放标签，非随机且不受控制。地点：巴西圣保罗的克洛尼卡·德·科诺基亚血液病（CLIOH）。患者与方法：从2002年6月至2003年4月，我们每天使用250 mg吉非替尼口服吉非替尼，治疗5例先前已转移的非小细胞肺癌转移患者（以前两次化疗方案的中位数）。阿斯利康赞助的富有同情心的协议。患者的中位年龄为65岁，其中两名是男性。在ECOG（东部合作肿瘤小组）量表上，三名患者的表现为1分，其中2分之一，3分之一。结果：我们观察到两名患者出现皮疹，三名出现腹泻，两名出现关节痛。通过影像学检查（分别持续了11个月和4个月以上），一名病人部分缓解，另一名病情稳定，同时肿瘤标志物明显减少，而三名病人在治疗期间恶化。讨论：迫切需要新的具有良好毒性特征的化学治疗药物来治疗通常预期寿命短的转移性非小肺癌患者。在我们的五个病人的小型系列中，我们观察到其中两个病人的疾病稳定，并且他们所有文献中经常描述皮肤和胃肠道反应。两人患有关节痛，以前没有报道。结论：我们得出结论，吉非替尼是转移性非小细胞肺癌患者重要治疗药物的补充。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号